HIF-1α-IN-2
Based on 4 publication(s) in Google Scholar
HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies (IC50s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translation.
For research use only. We do not sell to patients.
- Purity: 98.48%
- CAS No.: 2762315-06-8
- Formula: C21H19N3OS
- Molecular Weight:361.46
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
MCE Bioactive Compound Library
HY-L001V
-
Anti-Fibrosis Compound Library
HY-L185
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) HIF-1α-IN-2
More
Biological Activity
IC50: 28 nM (HIF-1α) in MDA-MB-231, 15 nM (HIF-1α) in MiaPaCa-2[1]
HIF-1α-IN-2 (compound 7f) (5 μM; 72h) suppresses the viability of MDA-MB-231 and MiaPaCa-2 cells with IC50s of 28 nM and 15 nM, respectively[1].
HIF-1α-IN-2 (0-1 μM; 72h) suppresses the expression of HIF-1α and VEGF with dose-dependent effect[1].
HIF-1α-IN-2 (0.25, 0.5, and 1 µM; 16-24h) can significantly inhibit the migration of MDA-MD-231 cells by 56% (0.25 µM), 83% (0.5 µM), and 85% (1 µM), respectively, and also noted in MiaPaCa-2 cells, which demonstrates the unique anti-migration effect of HIF-1α-IN-2[1].
HIF-1α-IN-2 (0-1 μM; 72h) suppresses HIF-1α mRNA levels in MDA-MB-231 cells under hypoxia[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells, MiaPaCa-2 cells[1]
-
Concentration:5 μM
-
Incubation Time:72 hours
-
Result:Suppressed the viability of these two cell lines with IC50 of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively.
-
Cell Line:MDA-MB-231 cells, MiaPaCa-2 cells[1]
-
Concentration:5 μM
-
Incubation Time:72 hours
-
Result:Suppressed the viability of these two cell lines with IC50 of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively.
Chemical Information
-
CAS No. 2762315-06-8
-
Appearance Solid
-
Molecular Weight 361.46
-
Formula C21H19N3OS
-
Color Off-white to light yellow
-
SMILES
CC1=NC(C2=CC(NC3=CC(C)=NC4=CC(OC)=CC=C34)=CC=C2)=CS1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]2026 Apr 21;7(4):102691. PMID: 41861828 -
Sci Rep
Catalpol regulates apoptosis and proliferation of endothelial cell via activating HIF-1α/VEGF signaling pathway. [Abstract]2024 Nov 16;14(1):28327. PMID: 39550364 -
Biology (Basel)
Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy. [Abstract]2024 Jul 31;13(8):577. PMID: 39194515 -
Arch Med Res
Mechanism of SENP1-Mediated Regulation of Liver Sinusoidal Endothelial Cells to Promote Regeneration Via the HIF-1α Signaling Pathway. [Abstract]2025 Aug 22;56(8):103295. PMID: 40848695
Solvent & Solubility
DMSO : 25 mg/mL (69.16 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7666 mL | 13.8328 mL | 27.6656 mL | 69.1639 mL |
| 5 mM | 0.5533 mL | 2.7666 mL | 5.5331 mL | 13.8328 mL | |
| 10 mM | 0.2767 mL | 1.3833 mL | 2.7666 mL | 6.9164 mL | |
| 15 mM | 0.1844 mL | 0.9222 mL | 1.8444 mL | 4.6109 mL | |
| 20 mM | 0.1383 mL | 0.6916 mL | 1.3833 mL | 3.4582 mL | |
| 25 mM | 0.1107 mL | 0.5533 mL | 1.1066 mL | 2.7666 mL | |
| 30 mM | 0.0922 mL | 0.4611 mL | 0.9222 mL | 2.3055 mL | |
| 40 mM | 0.0692 mL | 0.3458 mL | 0.6916 mL | 1.7291 mL | |
| 50 mM | 0.0553 mL | 0.2767 mL | 0.5533 mL | 1.3833 mL | |
| 60 mM | 0.0461 mL | 0.2305 mL | 0.4611 mL | 1.1527 mL |
HIF-1α-IN-2 Related Classifications
HY-115903 Related Classifications
Powered by Bioz